Principles of Clinical Pharmacology¶
Chapter 71 | Part 3: Pharmacology
KEY CLINICAL POINTS¶
- Pharmacogenomics plays a critical role in understanding variability in drug response due to genetic variants affecting pharmacokinetics/pharmacodynamics.
- Therapeutic index (drug concentration range between efficacy and toxicity) is essential for safe dosing, with narrow indices requiring careful monitoring.
- Drug interactions can significantly alter pharmacokinetics (absorption, metabolism, excretion) and pharmacodynamics, necessitating dose adjustments.
- Special populations (elderly, pediatric, renal/liver disease) require tailored dosing strategies to mitigate adverse effects.
- Therapeutic drug monitoring is crucial for drugs with narrow therapeutic indices or those with nonlinear pharmacokinetics.
1. DEFINITION & OVERVIEW¶
Clinical pharmacology focuses on understanding drug variability among individuals and optimizing therapy through pharmacogenomics and systems biology approaches. Drug actions vary due to genetic, environmental, and disease-related factors, requiring personalized treatment strategies.
Table 71-1: Molecular Pathways Mediating Drug Disposition¶
| ENZYME | SUBSTRATES | INHIBITORS |
|---|---|---|
| CYP3A | Calcium channel blockers, Antiarrhythmics, HMG-CoA reductase inhibitors | Amiodarone, Ketoconazole, Ritonavir |
| CYP2D6 | Tricyclic antidepressants, Codeine | Fluoxetine, Paroxetine |
| CYP2C9 | Warfarin, Phenytoin | Fluconazole, Phenobarbital |
| CYP2C19 | Omeprazole, Clopidogrel | Fluoxetine, Voriconazole |
| CYP2B6 | Efavirenz, Thiopurine | Ticlopidine, Ritonavir |
| N-acetyltransferase | Isoniazid, Procainamide | |
| UGT1A1 | Irinotecan | Rifampin |
| P-glycoprotein | Digoxin, Cyclosporine | Quinidine, Verapamil |
1.1 Therapeutic Index¶
The therapeutic index (TI) represents the ratio between the dose producing a therapeutic effect and the dose causing toxicity. A wide TI (e.g., 100) indicates safety, while a narrow TI (e.g., 50) requires precise dosing. TI is influenced by drug concentration-effect relationships and pharmacokinetic variability.
1.2 Systems Biology Approach¶
Modern pharmacology integrates systems biology to model complex drug-disease interactions, leveraging genomics, proteomics, and computational models to predict drug responses and optimize therapies.
2. EPIDEMIOLOGY¶
Drug response variability is universal across populations, influenced by genetic ancestry, adherence, and cultural factors. Adherence is preferred over 'compliance' to emphasize patient responsibility. Drug interactions and cost barriers affect treatment access and outcomes.
2.1 Risk-Benefit Balance¶
Benefits of drug therapy (symptom relief, disease prevention, prolonged survival) must outweigh risks. However, individual variability complicates risk-benefit assessment, especially in patients with comorbidities or life-threatening conditions.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Drug actions depend on pharmacokinetics (absorption, distribution, metabolism, excretion) and pharmacodynamics (drug-receptor interactions). Genetic variants in CYP enzymes, transporters (e.g., P-glycoprotein), and other pathways modulate drug metabolism and response.
Table 71-2: Drug Interactions¶
| MECHANISM | EXAMPLE |
|---|---|
| Pharmacokinetic Interactions Causing Decreased Drug Effect | Antacids reducing absorption of digoxin, ketoconazole |
| Pharmacokinetic Interactions Causing Increased Drug Effect | Cimetidine inhibiting CYP3A4, increasing warfarin levels |
| Pharmacodynamic Interactions | NSAIDs + ACE inhibitors causing hyperkalemia, nitrates + sildenafil causing hypotension |
3.1 Pharmacokinetic Variability¶
Absorption: Oral bioavailability is reduced by first-pass metabolism (e.g., digoxin, morphine). Distribution: Protein binding affects free drug concentrations. Metabolism: CYP enzymes (e.g., CYP3A4) mediate most drug metabolism. Excretion: Renal or hepatic clearance determines drug half-life.
3.2 Pharmacodynamic Variability¶
Drug-receptor interactions may be modulated by disease states (e.g., altered ion channels in cardiac arrhythmias) or genetic factors (e.g., CYP2D6 polymorphisms affecting codeine metabolism).
4. CLINICAL FEATURES¶
Drug effects vary by route of administration, disease state, and genetic factors. Adverse drug reactions (ADRs) may be dose-dependent (Type A) or unrelated to intended pharmacologic action (Type B).
4.1 Adverse Drug Reactions¶
Type A (dose-dependent): Exaggerated pharmacologic effects (e.g., bleeding with anticoagulants). Type B (idiosyncratic): Unrelated to drug mechanism (e.g., Stevens-Johnson syndrome, drug-induced lupus).
4.2 Drug-Induced Organ Toxicity¶
Acetaminophen hepatotoxicity, NSAID-induced renal failure, and drug-induced immune-mediated reactions (e.g., heparin-induced thrombocytopenia) are common complications.
5. DIFFERENTIAL DIAGNOSIS¶
Unusual drug responses may result from drug interactions, genetic polymorphisms, or disease states. For example, QT prolongation can arise from antiarrhythmics (e.g., sotalol) in renal failure or from drug interactions (e.g., CYP3A4 inhibitors).
6. INVESTIGATIONS & DIAGNOSIS¶
Therapeutic drug monitoring (TDM) is critical for drugs with narrow therapeutic indices (e.g., vancomycin, lithium). Plasma concentrations should be measured at trough levels for drugs with renal excretion and at peak levels for drugs with hepatic metabolism.
6.1 Drug Monitoring¶
TDM is used for anticonvulsants (e.g., phenytoin), immunosuppressants (e.g., cyclosporine), and antibiotics (e.g., vancomycin). Free drug concentrations are preferred for highly protein-bound drugs (e.g., phenytoin).
7. MANAGEMENT & TREATMENT¶
Dose adjustments are required for renal/liver dysfunction, drug interactions, and genetic polymorphisms. Therapeutic drug monitoring and pharmacogenetic testing (e.g., CYP2D6 genotyping) guide individualized therapy.
7.1 Dose Selection¶
Dosing is adjusted based on renal function (creatinine clearance), hepatic status, and drug interactions. For example, digoxin doses are reduced in renal failure, while clopidogrel bioavailability is decreased by proton pump inhibitors.
7.2 Special Populations¶
Elderly patients require cautious dosing due to altered pharmacokinetics and polypharmacy. Pediatric dosing is based on weight or body surface area, with limited evidence for specific age groups.
8. PROGNOSIS & COMPLICATIONS¶
ADRs can lead to severe complications (e.g., arrhythmias, organ failure) requiring immediate intervention. Long-term use of drugs (e.g., anticoagulants) necessitates monitoring for toxicity and adherence.
9. SPECIAL CONSIDERATIONS¶
Pregnancy, pediatrics, and geriatric patients require tailored dosing strategies. For example, warfarin doses are adjusted in pregnancy, and clopidogrel efficacy is reduced by proton pump inhibitors in elderly patients.
9.1 Drug Use in Pregnancy¶
Teratogenic drugs (e.g., isotretinoin) are contraindicated, while others (e.g., low-dose aspirin) are used cautiously. Fetal monitoring is essential for drugs with potential teratogenicity.
9.2 Pediatric Pharmacology¶
Dosing is based on weight or body surface area. Neonates and infants have immature hepatic and renal function, requiring lower doses and extended intervals.
10. KEY POINTS & CLINICAL PEARLS¶
Pharmacogenomics and systems biology are transforming drug therapy. Therapeutic drug monitoring is essential for high-risk drugs. Drug interactions and genetic variants must be considered in dosing adjustments. Special populations require individualized approaches to minimize ADRs.